By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Caliper Life Sciences today reported an 8 percent decrease in year-over-year revenues for its third quarter due to divestitures in 2009-2010, but on an organic basis revenues were up 11 percent.

The Hopkinton, Mass.-based firm had total revenues of $29.7 million for the three-month period ended Sept. 30, compared to $32.2 million for the third quarter of 2009. It beat analysts' consensus estimate for revenues of $27.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.